Grid Therapeutics, LLC, a Durham, N.C.-based biotechnology company developing the first human derived targeted immunotherapy for cancer, closed its Series A financing of undisclosed amount.
The round was led by Longview International, Ltd.
The company will use the proceeds to fund the antibody production and Phase 1 clinical trial of its lead candidate for the treatment of solid tumors.
Led by CEO Edward F. Patz, Jr. MD, Grid is developing a human derived targeted immunotherapy which leverages a novel approach of identifying specific tumor immunoglobulin G (IgG) antibodies from patients with early stage cancer obtaining the sequence of its lead IgG3 antibody directly from patients’ single B cells.
GT103, the company’s lead asset, is expected to enter a first-in-man Phase 1 clinical trial in advanced-stage solid tumor patients in early 2019.